Abstract:

Objective To investigate the efficacy of bevacizumab in combination with docetaxel to treat Her-2-negative metastatic breast cancer. Methods  Patients received either bevacizumab in combination with docetaxel（n＝42） or docetaxel（n=37）. Curative outcomes were assessed after 4 cycles of therapy during follow-up lasting 3-24 months. Results The total efficacy rate was 59.52% in the group receiving bevacizumab and docetaxel and 37.84% in the group receiving docetaxel，which was a significant difference（P>0.05）. The positive response rate was significantly higher in the group receiving bevacizumab and docetaxel （26.19 vs 24.32%，P<0.05），as was the 2-year survival rate（40.28 vs 16.22%，P<0.05）. At the same time，incidence of anemia and thrombocytopenia was significantly higher in the group receiving bevacizumab and docetaxel. Conclusion Bevacizumab combined with docetaxel can show high efficacy against Her-2-negative metastatic breast cancer，as well as improve the survival rate and survival time. Future studies need to examine ways to reduce the adverse effects of the therapy on blood components.

Key words: Breast neoplasm, Bevacizumab, Docetaxel, Recurrent metastatic breast cancer, HER-2